Aerie Pharmaceuticals Initiates Netarsudil Ophthalmic Solution Phase 2 Clinical Trial Designed to Meet Requirements of Regulatory Filing in Japan Thu, 16 Nov 2017 21:01:00 +0000 Aerie Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today announced the commencement of patient dosing in its Phase 2 clinical trial designed in accordance with the requirements of Japan’s PMDA for potential regulatory ...
Aerie reports 3Q loss Wed, 08 Nov 2017 21:07:32 +0000 On a per-share basis, the Irvine, California-based company said it had a loss of 89 cents. Losses, adjusted for stock option expense, were 71 cents per share. Aerie shares have increased 68 percent since ...
Aerie Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update Wed, 08 Nov 2017 21:01:00 +0000 Aerie Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today reported financial results for the third quarter ended September 30, 2017, along with a general business update.
Aerie Pharmaceuticals, Inc. to Host Earnings Call Wed, 08 Nov 2017 20:10:00 +0000 NEW YORK, NY / ACCESSWIRE / November 8, 2017 / Aerie Pharmaceuticals, Inc. (NASDAQ: AERI ) will be discussing their earnings results in their Q3 Earnings Call to be held on November 8, 2017 at 5:00 PM ...
Is a Surprise Coming for Aerie (AERI) This Earnings Season? Tue, 07 Nov 2017 13:36:01 +0000 Aerie Pharmaceuticals (AERI) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
Aerie Pharmaceuticals to Present at the Stifel 2017 Healthcare Conference Tue, 07 Nov 2017 12:30:00 +0000 Aerie Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today announced that Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer, will present in a fireside chat discussion at the Stifel 2017 Healthcare Conference ...
*Winners defined as our Top Picks that increased 20% or more within a 6-month period.
Red Letters imply that that particular criteria did not meet minimum requirements, e.g., a low GSA Rank would show it in red.
___ Red Line On Graph Shows a Trailing Stop Loss Based on Support and Resistance Levels. See how it works.
___ Blue Line On Graph Shows the 10-Week Moving Average.
___ Magenta Line On Graph Shows the 40-Week Moving Average.
Disclaimer The stock selections in our stock investing and stock trading database are not stock recommendations, but simply represent applications of a stock investing process. All materials, including our Top Stock Picks, are provided for information purposes only and should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security. Growth Stock Analytics, LLC is not responsible for gains/losses that may result in investing or trading in these securities. All information is believed to be obtained from reliable sources, but there is no guarantee that the information supplied is accurate, complete or timely. There is no guarantee or warranty with regard to the results obtained from its use. There is no guarantee of suitability or potential value of any particular investment or information source. You acknowledge that your requests for this information are unsolicited and shall neither constitute nor be considered investment advice. Past investing performance is not an indication of future performance results. Investing and trading in stocks is risky. Investors are encouraged to consult a registered stock broker or investment adviser before making any investing decisions. The interpretations and opinions expressed herein are solely those of Growth Stock Analytics, LLC, and not of any other individual or organization.